CompletedPhase 3

A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome

United States50 participantsStarted 2007-12

Plain-language summary

Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Cushing's Disease (that has recurred after primary pituitary surgery, or has failed pituitary surgery, or has been treated with radiation therapy to the pituitary, or is not treatable with surgery, or exists in patients who are not candidates for surgery, and is confirmed by documentation of ACTH immuno-reactivity on a pathological evaluation of pituitary tissue from a previous surgical specimen or IPSS with a central-to-peripheral gradient (ratio) of \>2 before or \>3 after CRH administration).
✓. Ectopic ACTH
✓. Ectopic CRF secretion
✓. Adrenal adenoma
✓. Adrenal carcinoma
✓. Adrenal autonomy

Improvement in Diabetes and/or Glucose Intolerance.

Timeframe: Baseline to Week 24

Decrease in Diastolic Blood Pressure.

Timeframe: Baseline to Week 24

NCT IDNCT00569582

SponsorCorcept Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-01

Results submitted2012-04-04